In a report released today, Laura Chico from Wedbush maintained a Buy rating on Edgewise Therapeutics (EWTX – Research Report), with a price ...

Edgewise Therapeutics' stock soars on positive Becker Muscular Dystrophy trial results. Learn why EWTX is a promising buy with derisked programs.

RBC Capital analyst Leonid Timashev maintained a Buy rating on Edgewise Therapeutics (EWTX – Research Report) today and set a price target of ...

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the company will present data on sevasemten, an investigational orally ...

Fintel reports that on March 7, 2025, Scotiabank initiated coverage of Edgewise Therapeutics (NasdaqGS:EWTX) with a Sector ...

In its fourth quarter 2024 investor letter, Baron Health Care Fund emphasized stocks such as Edgewise Therapeutics, Inc. (NASDAQ:EWTX). Edgewise Therapeutics, Inc. (NASDAQ:EWTX) is a ...

Equities researchers at Leerink Partnrs dropped their Q1 2025 earnings per share (EPS) estimates for shares of Edgewise ...

BOULDER, Colo., March 04, 2025--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the Leerink ...

Edgewise Therapeutics (NASDAQ:EWTX – Get Free Report)‘s stock had its “outperform” rating reissued by investment analysts at ...

Investors in Edgewise Therapeutics Inc (Symbol: EWTX) saw new options become available today, for the April 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down ...

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the company will present data on sevasemten ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...